16 November 2026
TheraCryf plc
(“TheraCryf”, the “Company” or the “Group”)
Investor Conference Attendance
TheraCryf plc (AIM: TCF), the biotechnology company developing new medicines for addiction and other neuropsychiatric disorders, is pleased to announce its participation in the following investor conferences.
Management will be available to meet existing shareholders and prospective investors and answer questions about TheraCryf and its lead Ox-1 addiction programme.
LSX Investival Showcase – 16 November 2026
Dr Huw Jones, Chief Executive Officer, will present at the LSX Investival Showcase at Old Billingsgate, London, today, 16 November 2026, at 11.45 am.
Further information is available at: https://informaconnect.com/investival-showcase/
Mello London – 17–18 November 2026
TheraCryf will attend Mello London at the Clayton Hotel & Conference Centre, Chiswick, London, on Tuesday, 17 November 2026 and Wednesday, 18 November 2026.
The Company will present from 10.40-11.10 am on Tuesday, 17 November 2026 and from 2.25-2.55 pm on Wednesday, 18 November 2026.
For further information and tickets (use code SHAREML25 for 25% off ticket price), please visit the event website at www.melloevents.com/mellolondon2026
These events follow the Company’s attendance at BIO-Europe in Cologne from 9–11 November 2026, where management met potential partners and industry colleagues to discuss TheraCryf’s development programmes.
The presentations will draw on information already in the public domain. No new material information will be disclosed.
-Ends-
Enquiries
|
TheraCryf plc Dr Huw Jones, CEO Toni Hänninen, CFO Dr Helen Kuhlman, COO
|
+44 (0)1625 315 090 |
|
Strand Hanson (Financial & Nominated Adviser)
|
+44 (0)20 7409 3494 |
|
Turner Pope Investments (Broker) Andy Thacker / Guy McDougall
|
+44 (0)20 3657 0050
|
|
Northstar Communications (Investor Relations) Sarah Hollins |
+44 (0)113 730 3896 sarah@northstarcommunications.co.uk
|
About TheraCryf
TheraCryf plc is a biotechnology company developing new medicines for addiction and other neuropsychiatric disorders, areas of significant unmet medical need.
The Group’s lead programme is a novel, best-in-class orexin-1 receptor antagonist being developed as a potential treatment for addiction, including binge eating, alcohol and other substance use disorders.
The programme has already been heavily de-risked for both safety/tolerability and efficacy in previous testing and is fully funded through final pre-clinical trials to clinical readiness, with regulatory submissions for first in man studies targeted for 2026.
TheraCryf also has a dopamine transporter (DAT) modulator programme addressing fatigue of brain origin, including fatigue associated with multiple sclerosis, chemotherapy and narcolepsy. The Group also has a legacy, grant-funded, oncology programme in glioblastoma with SFX-01.
The Group operates a capital-light, virtual development model advancing programmes to early clinical or proof-of-concept stage before partnering with commercially focused pharmaceutical and biotechnology companies.
TheraCryf’s headquarters and registered office are at Alderley Park, Cheshire.
For further information, visit: https://theracryf.com